UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study

Journal of clinical oncology, 2012-06, Vol.30 (17), p.2046-2054

2012

Volltextzugriff (PDF)

Subcutaneous envafolimab monotherapy in patients with advanced defective mismatch repair/microsatellite instability high solid tumors

Journal of hematology and oncology, 2021-06, Vol.14 (1), p.1-95, Article 95

2021

Volltextzugriff (PDF)

Phase I and Pharmacokinetic Study of Cetuximab and Irinotecan in Children With Refractory Solid Tumors: A Study of the Pediatric Oncology Experimental Therapeutic Investigators' Consortium

Journal of clinical oncology, 2009-10, Vol.27 (30), p.5102-5108

2009

Volltextzugriff (PDF)

Dihydroartemisinin and artesunate inhibit aerobic glycolysis via suppressing c-Myc signaling in non-small cell lung cancer

Biochemical pharmacology, 2022-04, Vol.198, p.114941-114941, Article 114941

2022

Volltextzugriff (PDF)

First‐in‐Human Phase I Study of Envafolimab, a Novel Subcutaneous Single‐Domain Anti‐PD‐L1 Antibody, in Patients with Advanced Solid Tumors

The oncologist (Dayton, Ohio), 2021-09, Vol.26 (9), p.e1514-e1525

2021

Volltextzugriff (PDF)

Phase 1b study of bavdegalutamide, an androgen receptor PROTACdegrader, combined with abiraterone in patients with metastatic prostate cancer

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS5106-TPS5106

2022

Volltextzugriff (PDF)

A phase 2 expansion study of ARV-766, a PROTACandrogen receptor (AR) degrader, in metastatic castration-resistant prostate cancer (mCRPC)

Journal of clinical oncology, 2023-02, Vol.41 (6_suppl), p.TPS290-TPS290

2023

Volltextzugriff (PDF)

MP14-19 ARV-766, A PROTAC ANDROGEN RECEPTOR (AR) DEGRADER, COMBINED WITH ABIRATERONE IN NOVEL HORMONAL AGENT (NHA)-NA VE METASTATIC PROSTATE CANCER: PHASE 1 COHORT (PART C) OF A PHASE 1/2 STUDY

The Journal of urology, 2024-05, Vol.211 (5S)

2024

Volltextzugriff (PDF)

ARV-471, an estrogen receptor (ER) PROTACdegrader, combined with palbociclib in advanced ER+/human epidermal growth factor receptor 2–negative (HER2-) breast cancer: Phase 1b cohort (part C) of a phase 1/2 study

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS1120-TPS1120

2022

Volltextzugriff (PDF)

Envafolimab plus chemotherapy in advanced gastric or gastroesophageal junction (G/GEJ) cancer

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.e16585-e16585

2020

Volltextzugriff (PDF)

Antitumor activity of a ROR1 × CD3 bispecific antibody in non-small cell lung cancer

International immunopharmacology, 2023-10, Vol.123, p.110686-110686, Article 110686

2023

Volltextzugriff (PDF)

Construction of amide-bonded supramolecular multifunctional fillers towards boosted self-healing, thermal conductivity and dielectric properties

Molecular systems design & engineering, 2024-09

2024

Volltextzugriff (PDF)

Phase 1/2 study of ARV-110, an androgen receptor (AR) PROTAC degrader, in metastatic castration-resistant prostate cancer (mCRPC)

Journal of clinical oncology, 2022-02, Vol.40 (6_suppl), p.17-17

2022

Volltextzugriff (PDF)

Envafolimab (KN035) in advanced tumors with mismatch-repair deficiency

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.3021-3021

2020

Volltextzugriff (PDF)

Phase I study of KN035, the first subcutaneously administered, novel fusion anti-PD-L1 antibody in patients with advanced solid tumors in China

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.2608-2608

2019

Volltextzugriff (PDF)

Phase I safety and pharmacokinetic study of KN035, the first subcutaneously administered, novel fusion anti-PD-L1 antibody in Japanese patients with advanced solid tumors

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.2609-2609

2019

Volltextzugriff (PDF)

Abstract CT178: Nivolumab monotherapy in patients with advanced platinum-resistant urothelial carcinoma: Efficacy and safety update and association between biomarkers and overall survival in CheckMate 275

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.CT178-CT178

2018

Volltextzugriff (PDF)

Abstract GS3-03: GS3-03 ARV-471, a PROTAC® estrogen receptor (ER) degrader in advanced ER-positive/human epidermal growth factor receptor 2 (HER2)-negative breast cancer: phase 2 expansion (VERITAC) of a phase 1/2 study

Cancer research (Chicago, Ill.), 2023-03, Vol.83 (5_Supplement), p.GS3-03-GS3-03

2023

Volltextzugriff (PDF)

OA03.05 Analysis of Early Survival in Patients with Advanced Non-Squamous NSCLC Treated with Nivolumab vs Docetaxel in CheckMate 057

Journal of thoracic oncology, 2017-01, Vol.12 (1), p.S253-S253

2017

Volltextzugriff (PDF)

Dual Inhibition of the Epidermal Growth Factor Receptor with Cetuximab, an IgG1 Monoclonal Antibody, and Gefitinib, A Tyrosine Kinase Inhibitor, in Patients with Refractory Non-small Cell Lung Cancer (NSCLC): A Phase I Study

Journal of thoracic oncology, 2008-03, Vol.3 (3), p.258-264

2008

Volltextzugriff (PDF)

Bayesian areal wombling via adjacency modeling

Environmental and ecological statistics, 2007-12, Vol.14 (4), p.433-452

2007

Volltextzugriff (PDF)

Bayesian Areal Wombling for Geographical Boundary Analysis

Geographical analysis, 2005-07, Vol.37 (3), p.265-285

2005

Volltextzugriff (PDF)

Dual Inhibition of the Epidermal Growth Factor Receptor Pathway with Cetuximab and Erlotinib: A Phase I Study in Patients with Advanced Solid Malignancies

The oncologist (Dayton, Ohio), 2009-02, Vol.14 (2), p.119-124

2009

Volltextzugriff (PDF)

Measuring the complexity of generalized linear hierarchical models

Canadian journal of statistics, 2007-03, Vol.35 (1), p.69-87

2007

Volltextzugriff (PDF)

Measuring the complexity of generalized linear hierarchical models and Bayesian areal wombling for boundary analysis

Lu, Haolan

2005

Volltextzugriff (PDF)

1 – 25 von 98

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(90)
Mit Volltextzugriff
(92)

Publikationsform

Sprache

Englisch
(98)

Erscheinungsjahr

n.n

Thema

Science & Technology
(60)
Technology
(37)
Physical Sciences
(22)
Life Sciences & Biomedicine
(21)
Materials Science
(17)
Materials Science, Multidisciplinary
(16)
Chemistry
(15)
Engineering
(15)
Chemistry, Physical
(12)
Computer Science
(12)
Science & Technology - Other Topics
(12)
Physics
(10)
Nanoscience & Nanotechnology
(9)
Chemistry, Multidisciplinary
(8)
Oncology
(8)
Physics, Applied
(7)
Physics, Condensed Matter
(7)
Computer Science, Artificial Intelligence
(6)
Humans
(6)
Energy & Fuels
(5)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(4)
... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study

Subcutaneous envafolimab monotherapy in patients with advanced defective mismatch repair/microsatellite instability high solid tumors

Phase I and Pharmacokinetic Study of Cetuximab and Irinotecan in Children With Refractory Solid Tumors: A Study of the Pediatric Oncology Experimental Therapeutic Investigators' Consortium

Dihydroartemisinin and artesunate inhibit aerobic glycolysis via suppressing c-Myc signaling in non-small cell lung cancer

First‐in‐Human Phase I Study of Envafolimab, a Novel Subcutaneous Single‐Domain Anti‐PD‐L1 Antibody, in Patients with Advanced Solid Tumors

Phase 1b study of bavdegalutamide, an androgen receptor PROTACdegrader, combined with abiraterone in patients with metastatic prostate cancer

A phase 2 expansion study of ARV-766, a PROTACandrogen receptor (AR) degrader, in metastatic castration-resistant prostate cancer (mCRPC)

MP14-19 ARV-766, A PROTAC ANDROGEN RECEPTOR (AR) DEGRADER, COMBINED WITH ABIRATERONE IN NOVEL HORMONAL AGENT (NHA)-NA VE METASTATIC PROSTATE CANCER: PHASE 1 COHORT (PART C) OF A PHASE 1/2 STUDY

ARV-471, an estrogen receptor (ER) PROTACdegrader, combined with palbociclib in advanced ER+/human epidermal growth factor receptor 2–negative (HER2-) breast cancer: Phase 1b cohort (part C) of a phase 1/2 study

Envafolimab plus chemotherapy in advanced gastric or gastroesophageal junction (G/GEJ) cancer

Antitumor activity of a ROR1 × CD3 bispecific antibody in non-small cell lung cancer

Construction of amide-bonded supramolecular multifunctional fillers towards boosted self-healing, thermal conductivity and dielectric properties

Phase 1/2 study of ARV-110, an androgen receptor (AR) PROTAC degrader, in metastatic castration-resistant prostate cancer (mCRPC)

Envafolimab (KN035) in advanced tumors with mismatch-repair deficiency

Phase I study of KN035, the first subcutaneously administered, novel fusion anti-PD-L1 antibody in patients with advanced solid tumors in China

Phase I safety and pharmacokinetic study of KN035, the first subcutaneously administered, novel fusion anti-PD-L1 antibody in Japanese patients with advanced solid tumors

Abstract CT178: Nivolumab monotherapy in patients with advanced platinum-resistant urothelial carcinoma: Efficacy and safety update and association between biomarkers and overall survival in CheckMate 275

Abstract GS3-03: GS3-03 ARV-471, a PROTAC® estrogen receptor (ER) degrader in advanced ER-positive/human epidermal growth factor receptor 2 (HER2)-negative breast cancer: phase 2 expansion (VERITAC) of a phase 1/2 study

OA03.05 Analysis of Early Survival in Patients with Advanced Non-Squamous NSCLC Treated with Nivolumab vs Docetaxel in CheckMate 057

Dual Inhibition of the Epidermal Growth Factor Receptor with Cetuximab, an IgG1 Monoclonal Antibody, and Gefitinib, A Tyrosine Kinase Inhibitor, in Patients with Refractory Non-small Cell Lung Cancer (NSCLC): A Phase I Study

Bayesian areal wombling via adjacency modeling

Bayesian Areal Wombling for Geographical Boundary Analysis

Dual Inhibition of the Epidermal Growth Factor Receptor Pathway with Cetuximab and Erlotinib: A Phase I Study in Patients with Advanced Solid Malignancies

Measuring the complexity of generalized linear hierarchical models

Measuring the complexity of generalized linear hierarchical models and Bayesian areal wombling for boundary analysis

Suchergebnisse filtern